Related Experiment Video
Updated: May 30, 2026
09:27
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
Drug targets from genetics: α-synuclein.
Karin M Danzer1, Pamela J McLean
1MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, 02129, USA.
CNS & Neurological Disorders Drug Targets
|August 16, 2011
Summary
Small, soluble alpha-synuclein (αsyn) oligomers, not large aggregates, are the toxic culprits in Parkinson disease (PD). Enhancing cellular degradation of misfolded αsyn offers a promising therapeutic target for PD.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathology
Background:
- Parkinson disease (PD) pathogenesis is linked to alpha-synuclein (αsyn) gene mutations or multiplication.
- Historically, large αsyn aggregates were considered the primary toxic species.
- Emerging evidence implicates smaller, soluble αsyn oligomers as the key toxic moiety.
Purpose of the Study:
- To review the fundamental mechanisms of αsyn toxicity in PD.
- To explore the role of oligomer formation, oxidative stress, and degradation pathways.
- To consider potential therapeutic strategies targeting αsyn pathogenesis.
Main Methods:
- Literature review of studies on αsyn toxicity and PD pathogenesis.
- Analysis of cellular mechanisms including protein misfolding and degradation.
- Evaluation of therapeutic strategies for PD.
Main Results:
- Soluble misfolded αsyn oligomers are increasingly recognized as the toxic species in PD.
- Fibrillar inclusions may represent a cellular detoxification mechanism.
- Cellular degradation pathways for misfolded αsyn are crucial for neuroprotection.
Conclusions:
- Targeting cellular mechanisms that degrade misfolded αsyn is a rational therapeutic strategy for PD.
- Understanding αsyn oligomerization and degradation is key to developing effective PD treatments.
- Interventions aimed at enhancing αsyn clearance could halt PD progression.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...